ArticleEuropean journal of heart failure2022
Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
Article in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- Comparative analysis of randomized versus real-world populations in heart failure: DIAMOND trial vs CARE-HK registry.ESC heart failure · 2026Trial
- Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial.American journal of nephrology · 2024Trial
- Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure.ESC heart failure · 2023Trial
- Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.European heart journal · 2022Trial
- Hyperkalemia management in heart failure and chronic kidney disease: a Spanish cost-effectiveness analysis of patiromer informed by the integrated DIAMOND trial and real-world evidence.BMC health services research · 2026Article
- Economic Evaluation of Patiromer in Patients with Concomitant Heart Failure and Chronic Kidney Disease in Italy.PharmacoEconomics - open · 2025Article
- 2024 update in heart failure.ESC heart failure · 2025Review
- Clinical implications of mineralocorticoid receptor overactivation.Clinical kidney journal · 2025Review
- EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease and Heart Failure.Cardiorenal medicine · 2025Review
- A Case-based Implementation of Heart Failure Therapies, a Consensus Pathway by the Saudi Heart Failure Working Group.Journal of the Saudi Heart Association · 2024Article
- Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Article
- Medical Treatment in Heart Failure with Reduced Ejection Fraction: A Proposed Algorithm Based on the Patient's Electrolytes and Congestion Status.Medical sciences (Basel, Switzerland) · 2023Review
- Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients.ESC heart failure · 2023Article
- Hyperkalemia: Prevalence, Predictors and Emerging Treatments.Cardiology and therapy · 2023Review
- Heart Failure Pharmacological Management: Gaps and Current Perspectives.Journal of clinical medicine · 2023Article
- Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease.Kidney diseases (Basel, Switzerland) · 2023Review
- Heart failure: an update from the last years and a look at the near future.ESC heart failure · 2022Review
- BLITZ-HF: a nationwide initiative to evaluate and improve adherence to acute and chronic heart failure guidelines.European journal of heart failure · 2022Article
- Review
- Advances in the area of cardiorenal medicine: clinical research highlights from selected papers published in NDT.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 16 institutions in 11 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsIn patients with current or a history of hyperkalaemia, treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K
methodsThe DIAMOND trial will enroll ∼820 patients with heart failure with reduced ejection fraction (HFrEF; ejection fraction ≤40%). Patients meeting the screening criteria will enter a single-blinded run-in phase where they will be started or continued on a mineralocorticoid receptor antagonist (MRA) titrated to 50 mg/day and other RAASi therapy to ≥50% target dose, and patiromer. Patiromer will be titrated up to a maximum three packs/day (8.4 g/pack) to achieve optimal doses of RAASi without hyperkalaemia. The run-in phase will last up to 12 weeks, following which patients will undergo double-blind randomization in a 1:1 ratio to receive either continued patiromer or placebo (patiromer withdrawal). The primary endpoint is the mean difference in serum K
conclusionThe DIAMOND trial is designed to determine if patiromer can favourably impact K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.